NO20064950L - Pyrimidlnderivater og fremgangsmater for behandling basert pa anvendelse av disse - Google Patents
Pyrimidlnderivater og fremgangsmater for behandling basert pa anvendelse av disseInfo
- Publication number
- NO20064950L NO20064950L NO20064950A NO20064950A NO20064950L NO 20064950 L NO20064950 L NO 20064950L NO 20064950 A NO20064950 A NO 20064950A NO 20064950 A NO20064950 A NO 20064950A NO 20064950 L NO20064950 L NO 20064950L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- depression
- compounds
- abuse
- methods
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 201000009032 substance abuse Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012218 Delirium Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 abstract 1
- 230000006993 memory improvement Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55740604P | 2004-03-30 | 2004-03-30 | |
| PCT/JP2005/006582 WO2005095357A2 (fr) | 2004-03-30 | 2005-03-29 | Derives de pyrimidine et procedes de traitement lies a l'utilisation de ceux-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064950L true NO20064950L (no) | 2006-12-29 |
Family
ID=35064444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064950A NO20064950L (no) | 2004-03-30 | 2006-10-30 | Pyrimidlnderivater og fremgangsmater for behandling basert pa anvendelse av disse |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090036448A1 (fr) |
| EP (1) | EP1730122A2 (fr) |
| JP (1) | JP2007530445A (fr) |
| KR (1) | KR20070013279A (fr) |
| CN (2) | CN101693695A (fr) |
| AU (1) | AU2005227997A1 (fr) |
| BR (1) | BRPI0509299A (fr) |
| CA (1) | CA2558915A1 (fr) |
| NO (1) | NO20064950L (fr) |
| NZ (1) | NZ549673A (fr) |
| RU (1) | RU2373197C2 (fr) |
| WO (1) | WO2005095357A2 (fr) |
| ZA (1) | ZA200607639B (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512844D0 (en) * | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| WO2007107470A2 (fr) | 2006-03-22 | 2007-09-27 | F. Hoffmann-La Roche Ag | Pyrazoles utiles comme inhibiteurs de 11-beta-hsd-1 |
| EP2007373A4 (fr) * | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | Inhibition de la toxicité de l'alpha-synucléine |
| CA2673586A1 (fr) | 2006-12-26 | 2008-07-24 | Amgen Inc. | N-cyclohexyl benzamides et benzene acetamides utilises comme inhibiteurs de 11-beta-hydroxysteroides deshydrogenases |
| JPWO2008093737A1 (ja) | 2007-01-31 | 2010-05-20 | 大日本住友製薬株式会社 | アミド誘導体 |
| CA2949336C (fr) * | 2007-08-02 | 2018-11-06 | Lei Zhu | Procede pour la synthese d'inhibiteurs de l'enzyme d'activation e1 |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| KR20110067026A (ko) * | 2008-10-02 | 2011-06-20 | 다이쇼 세이야꾸 가부시끼가이샤 | ７-피페리디노알킬-３,４-디히드로퀴놀론 유도체 |
| CN102421780A (zh) | 2009-05-14 | 2012-04-18 | 米伦纽姆医药公司 | 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐 |
| UA110097C2 (uk) | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| US8785453B2 (en) | 2009-11-13 | 2014-07-22 | Green Cross Corporation | Arylpiperazine-containing purine derivatives and uses thereof |
| CN102070618B (zh) * | 2009-11-23 | 2013-08-21 | 和记黄埔医药（上海）有限公司 | 一种化合物及其晶体 |
| JP2013533287A (ja) * | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
| WO2013113720A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| AU2013214137A1 (en) | 2012-02-03 | 2014-08-21 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113778A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| WO2013113773A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés fongicides de pyrimidine |
| WO2013113782A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| US9072301B2 (en) | 2012-02-03 | 2015-07-07 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113716A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| WO2013113719A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides ii |
| WO2013113791A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| WO2013113781A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides i |
| WO2013113776A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| JP6250561B2 (ja) | 2012-02-08 | 2017-12-20 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ヘテロアリール化合物およびそれらの使用方法 |
| EA201491667A1 (ru) | 2012-03-13 | 2015-03-31 | Басф Се | Фунгицидные соединения пиримидина |
| WO2013135672A1 (fr) | 2012-03-13 | 2013-09-19 | Basf Se | Composés de pyrimidine fongicides |
| WO2014195402A1 (fr) * | 2013-06-06 | 2014-12-11 | Chiesi Farmaceutici S.P.A. | Inhibiteurs de kinase |
| CN105722833A (zh) | 2013-09-16 | 2016-06-29 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
| WO2015036059A1 (fr) | 2013-09-16 | 2015-03-19 | Basf Se | Composés fongicides de pyrimidine |
| US10308648B2 (en) * | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN104592131A (zh) * | 2015-02-11 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 含嘧啶结构的对称环己烷羧酸苄基酰胺类化合物及用途 |
| CN104649981A (zh) * | 2015-02-11 | 2015-05-27 | 佛山市赛维斯医药科技有限公司 | 一种含嘧啶结构的对称环己烷羧酸苄基酰胺类双靶点抑制剂、制备方法及用途 |
| CN104628656A (zh) * | 2015-02-11 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | 一类含嘧啶结构的对称环己烷羧酸酰胺类双靶点抑制剂及用途 |
| CN104649980A (zh) * | 2015-02-11 | 2015-05-27 | 佛山市赛维斯医药科技有限公司 | 含嘧啶结构的对称环己烷羧酸酰胺类sglt2/sglt1双靶点抑制剂、制备方法及用途 |
| US10376511B2 (en) | 2015-08-04 | 2019-08-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pyrazole pyrimidine derivative and uses thereof |
| CN106632082B (zh) * | 2015-11-04 | 2020-10-09 | 中国科学院上海药物研究所 | 一类对gpr84具有激动作用的化合物及其制备方法和用途 |
| CA3026149A1 (fr) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Modulateurs des canaux potassiques |
| BR112019014814B1 (pt) | 2017-01-23 | 2024-03-12 | Novartis Ag | Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio |
| CA3116339A1 (fr) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Formes cristallines de modulateurs des canaux potassiques |
| JP2022540253A (ja) | 2019-07-11 | 2022-09-14 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法 |
| US10702525B1 (en) | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
| WO2024105007A1 (fr) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Composés induisant l'autophagie et leurs utilisations |
| CN120118069A (zh) * | 2023-12-08 | 2025-06-10 | 武汉人福创新药物研发中心有限公司 | Mrgprx2拮抗剂及用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4417163A1 (de) * | 1994-05-17 | 1995-11-23 | Hoechst Schering Agrevo Gmbh | Heterocyclylamino- und Heterocyclyloxy-cycloalkyl-Derivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| WO1996006086A1 (fr) * | 1994-08-23 | 1996-02-29 | Ube Industries, Ltd. | Derive de 4-cyclohexylaminopyrimidine, procede de production et produit utilise dans la lutte contre les parasites agrohorticoles |
| AU7692996A (en) * | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| CZ20004727A3 (cs) * | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
| US6432969B1 (en) * | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| NZ524974A (en) * | 2000-10-06 | 2005-10-28 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing 5-membered ring compound |
| WO2003028641A2 (fr) * | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Antagonistes du recepteur de la mch |
| US7473695B2 (en) * | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
| US20050009815A1 (en) * | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
| EP1450801A4 (fr) * | 2001-11-27 | 2010-10-27 | Merck Sharp & Dohme | Composes de 2-aminoquinoline |
| US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| WO2003070244A1 (fr) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagoniste des effets d'une hormone de concentration de melanine et son utilisation |
| SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
| EP1590334B1 (fr) * | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta |
| EP1464335A3 (fr) * | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Derivés de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du MCH |
| CN100475793C (zh) * | 2003-03-31 | 2009-04-08 | 大正制药株式会社 | 喹唑啉衍生物及其制备药物的用途 |
| JP2004315511A (ja) * | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Ｍｃｈ受容体アンタゴニスト |
-
2005
- 2005-03-29 US US10/599,505 patent/US20090036448A1/en not_active Abandoned
- 2005-03-29 RU RU2006138022/04A patent/RU2373197C2/ru not_active IP Right Cessation
- 2005-03-29 EP EP05721721A patent/EP1730122A2/fr not_active Withdrawn
- 2005-03-29 JP JP2006534511A patent/JP2007530445A/ja not_active Abandoned
- 2005-03-29 BR BRPI0509299-0A patent/BRPI0509299A/pt not_active IP Right Cessation
- 2005-03-29 WO PCT/JP2005/006582 patent/WO2005095357A2/fr not_active Ceased
- 2005-03-29 ZA ZA200607639A patent/ZA200607639B/en unknown
- 2005-03-29 NZ NZ549673A patent/NZ549673A/en unknown
- 2005-03-29 CN CN200910173887A patent/CN101693695A/zh active Pending
- 2005-03-29 CN CNA200580017519XA patent/CN1976905A/zh active Pending
- 2005-03-29 CA CA002558915A patent/CA2558915A1/fr not_active Abandoned
- 2005-03-29 KR KR1020067020312A patent/KR20070013279A/ko not_active Ceased
- 2005-03-29 AU AU2005227997A patent/AU2005227997A1/en not_active Abandoned
-
2006
- 2006-10-30 NO NO20064950A patent/NO20064950L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005227997A1 (en) | 2005-10-13 |
| JP2007530445A (ja) | 2007-11-01 |
| CA2558915A1 (fr) | 2005-10-13 |
| RU2373197C2 (ru) | 2009-11-20 |
| EP1730122A2 (fr) | 2006-12-13 |
| BRPI0509299A (pt) | 2007-09-18 |
| KR20070013279A (ko) | 2007-01-30 |
| NZ549673A (en) | 2010-03-26 |
| RU2006138022A (ru) | 2008-05-10 |
| US20090036448A1 (en) | 2009-02-05 |
| ZA200607639B (en) | 2008-05-28 |
| WO2005095357A2 (fr) | 2005-10-13 |
| WO2005095357A3 (fr) | 2006-01-19 |
| CN101693695A (zh) | 2010-04-14 |
| CN1976905A (zh) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064950L (no) | Pyrimidlnderivater og fremgangsmater for behandling basert pa anvendelse av disse | |
| HRP20050780A2 (hr) | Novitetni kvinolin, tetrahidrokvinazolin i derivati pirimidina, kao i metode tretmana koji se povezani s njihovim korištenjem | |
| TW200626152A (en) | Pyridine derivatives and pharmaceutical compositions and uses thereof | |
| DE502005006204D1 (de) | 8- ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als arzneimittel | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| ATE407938T1 (de) | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür | |
| WO2007149395A3 (fr) | Azoles dotés d'une activité inhibitrice enzymatique utilisant l'atp, compositions, et leurs utilisations | |
| CY1114165T1 (el) | Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης | |
| ATE433978T1 (de) | 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| ATE483692T1 (de) | Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| Vasbinder et al. | Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors | |
| Mohamed et al. | Design, synthesis and structure–activity relationship (SAR) studies of 2, 4-disubstituted pyrimidine derivatives: Dual activity as cholinesterase and Aβ-aggregation inhibitors | |
| DE502004011551D1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen | |
| ATE553095T1 (de) | Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden | |
| NO20092688L (no) | Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering | |
| TW200633957A (en) | Compounds | |
| DE602006009804D1 (de) | Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5 | |
| EP1817311A4 (fr) | Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer | |
| ATE519762T1 (de) | Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung | |
| ATE412632T1 (de) | Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| ATE467636T1 (de) | Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten | |
| Cai et al. | Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |